Printer Friendly Printed from http://www.researchandmarkets.com/reports/344048 Emerging Diagnostic Biomarkers in Ovarian Cancer Description: Worldwide, ovarian cancer (CaO) is the leading cause of death from gynecological cancer and the fourth most common cause of cancer death in women. In 2006, according to the American Cancer Society, 20,180 new cases of CaO will be diagnosed in the United States and 15,310 women will die from the disease. This high death rate results from the difficulty associated with detecting CaO at an early stage and the lack of effective therapies to treat advanced disease. As we discuss, physicians are unanimous in calling for the development of a diagnostic test that can identify CaO before it metastasizes. In this report, we examine the pathophysiology of CaO and describe current methods of screening for the cancer, the use of biomarkers to diagnose CaO, proteomic and genomic technologies that researchers are employing to identify and test biomarkers, emerging biomarkers, and the use of biomarkers to improve clinical trials of CaO treatments and ultimately to tailor treatment to the individual patient. Business Implications Serum proteomics may yield new biomarkers for the identification of CaO, enabling blood tests for the detection of the disease. The hope is that combining CaO-associated proteins into a multimarker assay may enable screening and improve the chances of detecting CaO in its early stages. Patients would then have a better chance of being cured or a longer median survival and therefore would receive more cycles of treatment. An increase in drug-treatment rates would boost revenue for drug companies with marketed CaO therapies. Identifying protein markers in the blood that indicate how CaO responds to therapy is another goal of researchers. Specific markers that will give gynecologic oncologists and their patients a better idea of how their disease is responding to treatment will enable them to change treatment if a patient’s tumor is not responding. It will also facilitate longer treatment durations because patients will be able to switch to more suitable therapies and hopefully enjoy longer survival times. The quest for biomarkers has led to advances in proteomics and DNA microarray analysis and improved understanding of the biology and genetics of CaO. This knowledge, in turn, has led to the identification of multiple molecular targets that may soon change the standard treatment of CaO. Several molecularly targeted (biologic) agents have already entered clinical trials, including angiogenesis inhibitors and epidermal growth factor inhibitors. Further developments in this field will bear more novel highly targeted therapies. These therapies, along with the identification of corresponding biomarkers, will pave the way for the “intelligent” treatment of CaO by identifying patients whose disease will respond to a specific treatment. A successful diagnostic or screening test for CaO has significant sales potential. Given the lack of definitive diagnostic tests for CaO and the poor prognosis for patients with metastasized disease, physicians are unanimous in emphasizing the need for earlier diagnosis. A CaO biomarker would greatly reduce the costs associated with drug development by enabling the selection of a more homogeneous patient population for smaller, more cost-effective clinical trials. A biomarker would also accelerate drug development by facilitating decisions regarding which agents to pursue in the early stages of clinical development. Contents: - Overview - Pathophysiology of Ovarian Cancer Characterization of Ovarian Epithelial Tumors Spread of Ovarian Cancer Staging Prognostic Factors Tumor Stage Peritoneal Fluid Cytology Tumor Histology Performance Status Age Volume of Residual Disease CA-125 Levels DNA Ploidy - Current Ovarian Cancer Screening - Current Ovarian Cancer Diagnosis - Value of a Biomarker for Ovarian Cancer - Technologies Used to Identify Ovarian Cancer Biomarkers Proteomics Genomics - Emerging Biomarkers - Biomarker Development - Improving Clinical Trial Design - Patient-Tailored Therapy - Outlook List of Tables Table 1 International Federation of Gynecology and Obstetrics (FIGO) Staging System for Primary Carcinoma of the Ovary Table 2 Select Emerging Biomarkers for the Diagnosis of Ovarian Cancer Table 3 Serum Biomarkers Evaluated for Their Ability to Detect Ovarian Cancer Table 4 Ongoing U.S. Clinical Trials Investigating Screening and Diagnostic Methods for Ovarian Cancer Ordering: Order Online - visit http://www.researchandmarkets.com/reports/344048 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 06:43:18 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Emerging Diagnostic Biomarkers in Ovarian Cancer Web Address: http://www.researchandmarkets.com/reports/344048 Office Code: OCHGMJITRPT Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) - Single User €1,036.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 06:43:18 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World